EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

被引:1346
作者
Kleer, CG
Cao, Q
Varambally, S
Shen, RL
Ota, L
Tomlins, SA
Ghosh, D
Sewalt, RGAB
Otte, AP
Hayes, DF
Sabel, MS
Livant, D
Weiss, SJ
Rubin, MA
Chinnaiyan, AM [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[4] Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48109 USA
[5] Univ Michigan, Sch Med, Dept Radiat Oncol, Ann Arbor, MI 48109 USA
[6] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA
[7] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[8] Univ Amsterdam, Swammerdam Inst Life Sci, Biocentrum Amsterdam, NL-1018 TV Amsterdam, Netherlands
[9] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
关键词
D O I
10.1073/pnas.1933744100
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The Polycomb Group Protein EZH2 is a transcriptional repressor involved in controlling cellular memory and has been linked to aggressive prostate cancer. Here we investigate the functional role of EZH2 in cancer cell invasion and breast cancer progression. EZH2 transcript and protein were consistently elevated in invasive breast carcinoma compared with normal breast epithelia. Tissue microarray analysis, which included 917 samples from 280 patients, demonstrated that EZH2 protein levels were strongly associated with breast cancer aggressiveness. Overexpression of EZH2 in immortalized human mammary epithelial cell lines promotes anchorage-independent growth and cell invasion. EZH2-mediated cell invasion required an intact SET domain and histone deacetylase activity. This study provides compelling evidence for a functional link between dysregulated cellular memory, transcriptional repression, and neoplastic transformation.
引用
收藏
页码:11606 / 11611
页数:6
相关论文
共 37 条
[1]   Validation of tissue microarray technology in breast carcinoma [J].
Camp, RL ;
Charette, LA ;
Rimm, DL .
LABORATORY INVESTIGATION, 2000, 80 (12) :1943-1949
[2]   Role of histone H3 lysine 27 methylation in polycomb-group silencing [J].
Cao, R ;
Wang, LJ ;
Wang, HB ;
Xia, L ;
Erdjument-Bromage, H ;
Tempst, P ;
Jones, RS ;
Zhang, Y .
SCIENCE, 2002, 298 (5595) :1039-1043
[3]  
Clark GM, 1996, DIS BREAST, P461
[4]   Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal polycomb sites [J].
Czermin, B ;
Melfi, R ;
McCabe, D ;
Seitz, V ;
Imhof, A ;
Pirrotta, V .
CELL, 2002, 111 (02) :185-196
[5]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[6]  
Gruvberger S, 2001, CANCER RES, V61, P5979
[7]   The hallmarks of cancer [J].
Hanahan, D ;
Weinberg, RA .
CELL, 2000, 100 (01) :57-70
[8]  
Harris J. R., 2000, DIS BREAST, P749
[9]   Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful? [J].
Hayes, DF ;
Trock, B ;
Harris, AL .
BREAST CANCER RESEARCH AND TREATMENT, 1998, 52 (1-3) :305-319
[10]   Prognostic factors in breast cancer: Current and new predictors of metastasis [J].
Hayes, DF ;
Isaacs, C ;
Stearns, V .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) :375-392